The AGO-DESKTOP I study (Ann Surg Oncol. 2006;13(12):1702‐1710.) provided a score for the prediction of complete cytoreduction in recurrent ovarian cancer (ROC), which could predict complete resection to no gross residual disease (NGR) in 79% of patients. This AGO SCORE was then validated prospectively in the subsequent AGO-DESKTOP II study, showing it could predict 76% of patients who would benefit from Secondary Cytoreductive Surgery (SeCRS). (Int J Gynecol Cancer. 2011;21(2):289‐295.). Finally, the AGO-DESKTOP III trial was designed to evaluate in a prospectively randomized multicenter setting whether SeCRS followed by platinum-based combination chemotherapy can improve overall survival (OS) compared with platinum-based combination chemotherapy alone in AGO SCORE-positive patients with platinum-sensitive (platinum-free interval > 6 months) ROC (PSROC). (J Clin Oncol. 2020 38:15_suppl, 6000-6000) Accordingly, a patient’s selection for SeCRS by a positive AGO SCORE resulted in a meaningful survival benefit in terms of both OS and progression-free survival (PFS), but exclusively in those underwent SeCRS reaching NGR (74.2% of patients in the AGO-DESKTOP III Study). (J Clin Oncol. 2020 38:15_suppl, 6000-6000) At the time of first relapse, 51% of patients with PSROC are AGO SCORE-positive according to AGO-DESKTOP II study, (Int J Gynecol Cancer. 2011;21(2):289‐295.) but these patients should also be comprehensively evaluated regarding their eligibility for SeCRS based on addictional imaging plus patients and tumor characteristics.
This algorithm is provided for educational, training and information purposes. It must not be used to support medical decision making, or to provide medical or diagnostic services. Read our full disclaimer.
With an Evidencio Community account you can:
A personal Evidencio account is free, with no strings attached!
Join us and help create clarity, transparency, and efficiency in the creation, validation, and use of medical prediction algorithms.
{{ (typeof row === 'object') ? row.label : row }} |
{{ column }} | |
---|---|
{{ row.label }} | {{ value }} |
Please enter a password
A password has to be at least 8 characters.
A password cannot be longer then 64 characters.
Choose a password with at least one capital letter.
Choose a password with at least one special character (@$!%*#?&)
Please agree to the Terms & Conditions and the Disclaimer
Please provide your e-mail address and we'll send you a link to reset your password.
Email Address
Please enter a valid email
If an account was registered with this email address you will receive a recovery link in your mail.
Please use the reset password link in it to set your new password.
Didn't receive the email yet? Please check your spam folder, or resend the email.